All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
LONDON – The UK's National Institute for Health and Care Excellence (NICE) has issued guidelines to support the systematic introduction of biosimilar infliximab to replace the innovator product, Remicade.
